8-K: NKGen Biotech Secures $2 Million Investment Amidst OTC Market Transition and Filing Delays

NKGen Biotech, Inc. announced a $2 million private placement with Japanese strategic investor HekaBio K.K. to fund operations and regain SEC reporting compliance, while facing a temporary move to the OTC Expert Market due to filing delays.

Summary

• NKGen Biotech, Inc. (NKGN) entered into a Stock Purchase Agreement with HekaBio K.K. on July 14, 2025.
• HekaBio K.K. purchased 8,000,000 shares of common stock at $0.25 per share, for an aggregate purchase price of $2,000,000.00.
• NKGen also issued a common stock purchase warrant to HekaBio K.K. to purchase up to 8,000,000 shares of common stock, exercisable at $0.25 per share, expiring on July 14, 2030.
• The offering was made in reliance upon the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933 and Rule 506 of Regulation D.
• The company received notice from OTC Markets Group that its common stock quotations will move from OTC Pink to the Expert Market on or about July 17, 2025, due to failure to meet current SEC filing requirements.
• The move to the Expert Market will restrict public access to bid/ask prices and trading volume, making shares more illiquid, though they remain tradable through brokers.
• The company is diligently working to complete and file its Form 10-K for the year ended December 31, 2025, and Form 10-Q for the period ended March 31, 2025, to become current with reporting obligations.
• NKGen has applied for listing on the OTCQB Market, pending compliance with reporting obligations, and is committed to uplisting to Nasdaq or NYSE American once requirements are met.
• The new funding is intended to provide necessary resources to regain compliance, support the ramping up of its Phase 2 clinical trial for troculeucel, and satisfy a previously disclosed payment obligation on senior secured debt.
• The company also secured a majority stake in its former parent company, NKMax Co., Ltd., out of bankruptcy, which is expected to officially close in the coming month, consolidating key intellectual property rights across Asia.

Sentiment

Score: 4

Explanation: While new funding is a positive, the immediate negative impact of moving to the OTC Expert Market due to non-compliance, coupled with past financial challenges and the illiquidity this creates for investors, weighs heavily. The future plans are positive, but the current situation is challenging.

Positives

• Secured $2,000,000.00 in new capital from a Japanese strategic investor, HekaBio K.K.
• The new funding provides necessary resources to regain compliance with reporting obligations and listing standards.
• The company is ramping up its Phase 2 clinical trial for troculeucel, a novel NK cell therapy.
• Expected near-term satisfaction of public company reporting requirements.
• Satisfaction of previously disclosed payment obligation on senior secured debt.
• Successfully acquired a majority stake in former parent company NKMax Co., Ltd. out of bankruptcy, consolidating key intellectual property rights across Asia.
• The NKMax acquisition has sparked renewed interest from U.S. and international investors.
• Shareholders approved a reverse split on February 25, 2025, intended to aid in compliance with share price requirements for potential uplisting to major exchanges.

Negatives

• Failed to meet SEC filing requirements under the Exchange Act.
• Quotations in common stock will be moved from OTC Pink to the OTC Expert Market on or about July 17, 2025.
• Expert Market restrictions mean most investors will not be able to easily buy or sell shares and will lack access to bid/ask prices or trading volume, leading to increased illiquidity.
• The company faced significant external challenges, including the unexpected bankruptcy of its former parent company, NKMax Co., Ltd., in June 2024.
• Operational challenges due to limited financial resources led to unavoidable delays in financial filings.
• The move to the Expert Market will make it more difficult for investors to freely trade the shares of NKGen during the period until filing compliance is regained.

Risks

• Shares traded on the OTC Expert Market are more illiquid, making it difficult for investors to buy or sell.
• The company's ability to complete and file its Form 10-K for the year ended December 31, 2025, and Form 10-Q for the period ended March 31, 2025, as soon as possible to regain compliance.
• Potential delays in the commencement, enrollment, and completion of clinical studies and the reporting of data therefrom.
• The risk that initial and interim results of a clinical study do not necessarily predict final results and that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data become available.
• The company's ability to raise additional funding to complete the development of its product candidates.
• The risk that studies will not be completed as planned.
• The risk that the abstract will not be published as planned, including delays in timing, format, or accessibility.

Future Outlook

NKGen Biotech plans to diligently complete and file its overdue Form 10-K for December 31, 2025, and Form 10-Q for March 31, 2025, to regain compliance with SEC reporting obligations. The company has applied for listing on the OTCQB Market, pending compliance, and is committed to uplisting to Nasdaq or NYSE American once it meets the requirements, including leveraging a previously approved reverse split. The new funding will support the ramping up of its Phase 2 clinical trial for troculeucel and the satisfaction of senior secured debt obligations. The acquisition of a majority stake in NKMax Co., Ltd. is expected to close in the coming month, consolidating intellectual property rights across Asia and potentially leading to new strategic relationships and plans in the region.

Management Comments

• "This past year presented significant external challenges, particularly stemming from the unexpected bankruptcy of our former parent company, NKMax Co., Ltd. in June 2024. This event initially disrupted our ability to raise capital in the U.S. despite the encouraging progress we continued to make in our clinical trials and compassionate use cases. However, our team remained focused and committed to our mission. Through disciplined execution of our science and clinical programs, we not only sustained our momentum but also succeeded in securing the capital necessary to acquire a majority stake in NKMax out of bankruptcy, as previously disclosed. This transaction, expected to officially close in the coming month, removes a major overhang and allows us to consolidate key intellectual property rights across Asia. This strategic acquisition has already sparked renewed interest from both U.S. and international investors. We look forward to sharing further details in the near future about NKMax and strategic relationships and plans in Asia." Paul Y. Song, M.D., Chairman and Chief Executive Officer of NKGen.
• "This marks our first strategic investor in an important market for our therapy for Alzheimers and other neurodegenerative diseases. As in our other recently announcing funding, this new funding comes at a pivotal time for the Company, which has faced operational challenges due to limited financial resources and the need to make hard decisions on our use of cash, including the unfortunate but unavoidable delay in our financial filings. With all the necessary service providers fully engaged on the effort now, we’re on track to regain compliance in the near term. The Company has been informed by the OTC Markets Group that its trading will move from OTC Pink to the Expert Market until it regains compliance in its financial filings. The Expert Market allows for limited trading but does not allow public access to bid and ask prices or other information, including trading volume. Instead, pricing information will only be accessible to brokers and market makers. The move will make it more difficult for investors to freely trade the shares of NKGen during this short period until we regain filing compliance. We take our filing obligations seriously and greatly regret the short-term impact resulting from our prior limited access to capital. We ask our investors for patience during this time, after which we expect to emerge on OTCQB and later back on Nasdaq well-positioned for the future." James Graf, NKGen’s Interim Chief Financial Officer.

Industry Context

NKGen Biotech operates in the clinical-stage biotechnology sector, specializing in the development of autologous and allogeneic natural killer (NK) cell therapeutics. Its lead candidate, troculeucel, is being developed for neurodegenerative disorders like Alzheimer's and various cancers. The company's strategic acquisition of a majority stake in its former parent, NKMax Co., Ltd., out of bankruptcy, aims to consolidate intellectual property rights across Asia, indicating a focus on expanding its global footprint and leveraging its therapeutic pipeline in key international markets, particularly Japan, given the new strategic investor.

Corporate Governance

Stakeholder Impact

• Shareholders: Immediate negative impact due to move to OTC Expert Market, leading to reduced liquidity and transparency. Potential long-term positive impact from regained compliance, uplisting, and strategic growth.
• Investors (new): HekaBio K.K. gains a strategic stake and warrants, aligning with the company's future in the Japanese market.
• Employees: Continued operations and clinical programs, potentially stabilizing employment.
• Patients: Continued development of troculeucel through Phase 2 clinical trials.
• Creditors: Satisfaction of previously disclosed payment obligation on senior secured debt.

Next Steps

• Diligently complete and file Form 10-K for year ended December 31, 2025, and Form 10-Q for period ended March 31, 2025, to become current with Exchange Act reporting obligations.
• Regain compliance to facilitate listing on the OTCQB Market.
• Uplist back to Nasdaq or NYSE American as soon as requirements are met, including SEC filing compliance, minimum market capitalization, public float, and minimum share price.
• Close the acquisition of a majority stake in NKMax Co., Ltd. in the coming month.
• Share further details about NKMax and strategic relationships and plans in Asia.
• Continue ramping up Phase 2 clinical trial for troculeucel.

Key Dates

Recommendation

Keywords

NKGen Biotech, NKGN, HekaBio K.K., Stock Purchase Agreement, Private Placement, Common Stock, Warrants, SEC Filings, Form 8-K, OTC Expert Market, OTC Pink, OTCQB, Nasdaq, NYSE American, Compliance, Financial Reporting, Biotechnology, Clinical Stage, NK Cell Therapy, Troculeucel, Neurodegenerative Diseases, Cancer, NKMax Co., Ltd., Capital Raise, Illiquidity, Corporate Governance, Reverse Split